Market Cap
$23.9B
GH
Guardant Health, Inc.
$177.80 ▲ +1.75%
Prev close $174.75Market cap$23.9B
ConsensusStrong Buy
12-mo target$197.44 (+11.0%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (4 insiders)High Impact Filing (7/10)32 New Institutional Positions18 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on GH right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
50 funds
Inst. Value
$14.0B
Inst. Activity
32 buys / 18 sells
Insider Activity
$0.00 buy / $30.7M sell
Insider Net $
-$30.7M
Social Sentiment
67° Warm
SEC Reports
20
Price chart 30d +10.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 21, 2026 Insider
MIGNONE ROBERTO acquired via exercise 264 shares
Director
Sep 17, 2026 Insider
Hidalgo Medina Manuel acquired via exercise 232 shares
Director
Sep 16, 2026 Insider
Tariq Musa sold 116 shares
Director @ $175.00 ($20.3K)
Sep 14, 2026 short_volume
Aug 25, 2026 SEC Short Volume: GH — 55.5% short (0.4M / 0.7M)
Short: 363,154 | Exempt: 0 | TRF Vol: 654,281 | Short Ratio: 55.5% | Off-exchange volume (dark pool
Guardant Health (GH) insiders sold $1.54M in shares over the past week, led by Co-CEO AmirAli Talasaz who sold $1.52M in
CLUSTER — Impact 2/10
Two Guardant Health insiders — the Chief People Officer and Chief Commercial Officer — sold a combined $3.03M in open-ma
CLUSTER — Impact 3/10
A cluster of insider selling at Guardant Health (GH) totaling $6.73M in open-market sales over an 8-day window, led by t
CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — TRIM
7,622,935 shares ($1.1B)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 35 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Sep 9, 2026 | UBS | MAINTAIN | Buy | 55% |
| Sep 8, 2026 | Rothschild & Co | INITIATE | Buy | 58% |
| Sep 2, 2026 | BTIG | REITERATE | Buy | 53% |
| Aug 4, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 4, 2026 | Stephens & Co. | MAINTAIN | Overweight | 54% |
| Aug 4, 2026 | Morgan Stanley | MAINTAIN | Overweight | 55% |
| Aug 3, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Jul 31, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 31, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 15 | 17 | 3 | 0 | 0 | 91% | |
| Aug 1, 2026 | 15 | 17 | 3 | 0 | 0 | 91% | |
| Jul 1, 2026 | 15 | 18 | 2 | 0 | 0 | 94% | |
| Jun 1, 2026 | 14 | 15 | 3 | 0 | 0 | 91% | |
| May 1, 2026 | 14 | 15 | 4 | 0 | 0 | 88% | |
| Apr 1, 2026 | 14 | 16 | 4 | 0 | 0 | 88% | |
| Mar 1, 2026 | 14 | 16 | 4 | 0 | 0 | 88% | |
| Feb 1, 2026 | 12 | 17 | 3 | 0 | 0 | 91% |
Price targets
Where 25 covering analysts think GH trades over the next 12 months.
$197.44 +11.0% upside Buy
Current$177.80 Low$105.00 Median$200.00 High$225.00 25 analysts
$105.00$225.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 17 neutral · avg impact 3.0/10.
NEUTRALCLUSTER2/10
Guardant Health (GH) insiders sold $1.54M in shares over the past week, led by Co-CEO AmirAli Talasa
Aug 25, 2026
NEUTRALCLUSTER3/10
Two Guardant Health insiders — the Chief People Officer and Chief Commercial Officer — sold a combin
Aug 18, 2026
NEUTRALCLUSTER4/10
A cluster of insider selling at Guardant Health (GH) totaling $6.73M in open-market sales over an 8-
Aug 14, 2026
NEUTRALCLUSTER2/10
Three Guardant Health insiders, including the Chief Commercial Officer and two directors, sold a tot
Aug 12, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 14, 2026
short_volume
Short Volume: GH — 55.5% short (0.4M / 0.7M)
Short: 363,154 | Exempt: 0 | TRF Vol: 654,281 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
Sep 7, 2026
dark_pool
Dark Pool: GH — 1.4M shares, 41,515 trades
Week starting 2026-09-07. Total ATS volume: 1,388,810 shares across 41,515 trades.
Sep 2, 2026
short_volume
Short Volume: GH — 59.4% short (0.4M / 0.6M)
Short: 369,451 | Exempt: 1,209 | TRF Vol: 622,222 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
Aug 31, 2026
dark_pool
Dark Pool: GH — 2.9M shares, 55,175 trades
Week starting 2026-08-31. Total ATS volume: 2,948,960 shares across 55,175 trades.
Aug 31, 2026
ftd
FTD: GH — 5,051 shares ($0.8M) failed to deliver
Settlement: 20260831, Price: $161.50, FTD Value: $815,736.5, GUARDANT HEALTH INC COM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.31 | $-0.39–$-0.22 | 20.2% | -2.3% | 8↑ 8↓ | $0.4B | 17 |
| Next Q | $-0.28 | $-0.57–$-0.17 | 43.0% | -1.1% | 7↑ 9↓ | $0.4B | 17 |
| Current FY | $-1.47 | $-1.81–$-1.18 | 19.1% | -1.1% | 6↑ 11↓ | $1.4B | 21 |
| Next FY | $-0.42 | $-1.43–$0.71 | 71.6% | +5.5% | 10↑ 8↓ | $1.8B | 19 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.311 | — |
| 7d ago | $-0.307 | -0.004 |
| 30d ago | $-0.304 | -0.007 |
| 60d ago | $-0.305 | -0.006 |
| 90d ago | $-0.302 | -0.009 |
Institutional ownership
Which big funds own GH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $14.0B total value (93,471,355 shares) as of 2026-Q2. Top holders: NOMURA, BlackRock,, VANGUARD. Net buying activity: 32 institutions added/increased vs 18 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 7,622,935 | $1.1B | 8.2% | TRIM -34.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,755,857 | $863.6M | 6.2% | — |
| FMR LLC | 5,488,272 | $823.4M | 5.9% | ADD +33.3% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,445,785 | $817.0M | 5.9% | — |
| Invesco Ltd. | 4,429,755 | $664.6M | 4.8% | — |
| GOLDMAN SACHS GROUP INC | 3,775,895 | $566.5M | 4.1% | — |
| TWO SIGMA INVESTMENTS, LP | 3,719,301 | $558.0M | 4.0% | — |
| Capital International Investors | 3,399,604 | $510.0M | 3.7% | — |
| FRANKLIN RESOURCES INC | 3,236,065 | $485.5M | 3.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | TRIM | 11,553,759 | 7,622,935 | -34.0% | $1.1B |
| FMR LLC | ADD | 4,116,081 | 5,488,272 | +33.3% | $823.4M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 1,414,886 | 3,150,897 | +122.7% | $472.8M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | 3,508,883 | 2,521,596 | -28.1% | $378.4M |
| BAILLIE GIFFORD & CO | TRIM | 3,859,046 | 2,284,127 | -40.8% | $342.7M |
| JANE STREET GROUP, LLC | DOUBLED | 4,803 | 1,783,444 | +37031.9% | $267.6M |
| MILLENNIUM MANAGEMENT LLC | ADD | 921,395 | 1,622,458 | +76.1% | $243.4M |
| NORGES BANK | NEW | — | 1,548,518 | — | $232.3M |
| Artisan Partners Limited Partnership | ADD | 814,571 | 1,478,928 | +81.6% | $221.9M |
| CITADEL ADVISORS LLC | ADD | 775,941 | 1,449,534 | +86.8% | $217.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net -$30.7M — $0.00 bought, $30.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | MIGNONE ROBERTO | Director | EXERCISE | 264 | — | — |
| Sep 17, 2026 | Hidalgo Medina Manuel | Director | EXERCISE | 232 | — | — |
| Sep 16, 2026 | Tariq Musa | Director | SELL | 116 | $175.00 | $20.3K |
| Sep 16, 2026 | Krognes Steve E. | Director | SELL | 1,103 | $174.46 | $192.4K |
| Sep 16, 2026 | Krognes Steve E. | Director | SELL | 3,300 | $175.42 | $578.9K |
| Sep 16, 2026 | Azar Alex M II | Director | SELL | 826 | $175.00 | $144.6K |
| Sep 16, 2026 | Krognes Steve E. | Director | SELL | 1,300 | $176.34 | $229.2K |
| Sep 16, 2026 | Krognes Steve E. | Director | SELL | 971 | $177.48 | $172.3K |
| Sep 15, 2026 | Tariq Musa | Director | EXERCISE | 249 | — | — |
| Sep 15, 2026 | Chudova Darya | Chief Technology Officer | SELL | 7,738 | $178.00 | $1.4M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GH.
Shares short
11,018,331
Settlement Sep 15, 2026
Change vs prior
-0.3%
Semi-monthly cycle
Days to cover
6.6
At avg daily volume
Of shares outstanding
≈8.2%
Estimate — not % of float
All GH filing & press-release reports (26)
- CLUSTER reportAug 25, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportAug 14, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 11, 2026
- CLUSTER reportAug 6, 2026
- S-3ASR reportJul 30, 2026
- CLUSTER reportJun 30, 2026
- 144 reportJun 23, 2026
- COURT-RULING reportJun 17, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 12, 2026
- CLUSTER reportJun 5, 2026
- 144 reportJun 5, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 1, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 28, 2026
- COURT-RULING reportMay 28, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 22, 2026
- CLUSTER reportMay 22, 2026
- 144 reportMay 12, 2026
- DEFA14A reportApr 28, 2026
- 8-K reportApr 27, 2026
- CLUSTER reportMar 23, 2026